title: Dose-response to a jelly preparation of calcium polystyrene sulfonate in patients with hyperkalemia--changes in serum potassium levels with or without a RAAS inhibitor.
abstract: OBJECTIVE
  In this study, dose-response of the serum potassium-lowering effect of a calcium polystyrene sulfonate (PS) preparation was investigated. Changes in the serum potassium level were also examined with or without application of a RAAS inhibitor, which is said to increase the serum potassium level.
  
  
  METHODS
  23 patients diagnosed to have hyperkalemia associated with chronic renal failure were enrolled in this study. The study drug, a PS-Ca jelly preparation (Argamate jelly), was started at a daily dose of 1 preparation (5 g as PS-Ca), and the dose was increased by 1 preparation every month to finally reach 3 preparations per day. Blood samples were collected once a month and serum levels of creatinine and electrolytes were measured.
  
  
  RESULTS
  PS-Ca jelly decreased serum potassium levels in a dose-dependent manner. Decreases were 0.67 mEq/l at 5 g of PS-Ca/day, 1.06 mEq/l at 10 g/d, and 1.33 mEq/l at 15 g/d. Irrespective of the use of the RAAS inhibitor, serum potassium levels decreased significantly in a dose-dependent manner. Furthermore, no major change in serum creatinine levels occurred in subjects in which the RAAS inhibitor was used, although in subjects in which the RAAS inhibitor was not used, serum creatinine level tended to gradually increase.
  
  
  CONCLUSIONS
  Serum potassium levels were reduced in a dose-dependent manner by administration of 5-15 g/d of PS-Ca, and it appeared that together with control of serum potassium levels, renal function should be maintained by continuous administration of RAAS inhibitor.
authors.affiliation: Department of Internal Medicine, Division of Nephrology, Juntendo University School of Medicine, Bunkyo-Ku, Tokyo, Japan. yasu@med.juntendo.ac.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Tomino
authors.forename: T
authors.initials: T
authors.lastname: Yamazaki
authors.forename: I
authors.initials: I
authors.lastname: Shou
authors.forename: T
authors.initials: T
authors.lastname: Tsuge
authors.forename: K
authors.initials: K
authors.lastname: Satake
authors.forename: Y
authors.initials: Y
authors.lastname: Takeda
authors.forename: A
authors.initials: A
authors.lastname: Ohtani
authors.forename: T
authors.initials: T
authors.lastname: Nishitani
authors.forename: A
authors.initials: A
authors.lastname: Kurusu
authors.forename: C
authors.initials: C
authors.lastname: Hamada
authors.forename: S
authors.initials: S
authors.lastname: Horikoshi
authors.forename: K
authors.initials: K
authors.lastname: Maeda
authors.forename: Y
authors.initials: Y
authors.lastname: Tanaka
authors.forename: H
authors.initials: H
authors.lastname: Fukuda
authors.forename: M
authors.initials: M
authors.lastname: Wakabayashi
authors.forename: T
authors.initials: T
authors.lastname: Seto
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004304:Dosage Forms; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D006947:Hyperkalemia / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011137:Polystyrenes / Q000627:therapeutic use*; D011188:Potassium / Q000097:blood; D012084:Renin-Angiotensin System / Q000187:drug effects*
chemical_list: D004304:Dosage Forms; D011137:Polystyrenes; C003321:polystyrene sulfonic acid; D011188:Potassium